RAMPART Trial: Durvalumab Monotherapy Lacks DFS Benefit in Resected RCC; Combination Shows Benefit in High-Risk Patients
The phase 3 RAMPART trial updated results show adjuvant durvalumab monotherapy did not significantly improve disease-free survival in resected renal cell carcinoma, while the durvalumab plus tremelimumab combination showed benefit in high-risk patients. Real-world treatment decisions are also shaped by patient-specific factors.